Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zheng Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1396-2634; OpenAlex author ID A5100459096. Sources: OpenAlex.

Their work

Papers
18
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 5 papers · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 18

  1. Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition. Co-author DOI 10.3724/abbs.2023288↗
  2. Reshaping the Pancreatic Cancer Microenvironment at Different Stages with Chemotherapy. Co-author DOI 10.3390/cancers15092448↗
  3. The Crosstalk Between Immune Infiltration, Circulating Tumor Cells, and Metastasis in Pancreatic Cancer: Identification of HMGB3 From a Multiple Omics Analysis. Co-author DOI 10.3389/fgene.2022.892177↗
  4. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1002/ctm2.398↗
  5. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.11.023↗
  6. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Co-author DOI 10.1093/abbs/gmab074↗
  7. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-0414↗
  8. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Co-author DOI 10.1038/s41388-020-01452-3↗
  9. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  10. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗
  11. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.024↗
  12. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Co-author DOI 10.1111/cpr.12603↗
  13. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-019-0767-4↗
  14. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Co-author DOI 10.1186/s12964-019-0344-4↗
  15. FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. Co-author PMID 31911852↗
  16. Role of angiogenesis in pancreatic cancer biology and therapy. Co-author DOI 10.1016/j.biopha.2018.09.136↗
  17. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Co-author DOI 10.1111/cpr.12456↗
  18. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.13212↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shunrong Ji · 14 shared papers, 2018–2021 · strength 1.36
  2. Yi Qin · 14 shared papers, 2018–2021 · strength 1.36
  3. Qiangsheng Hu · 13 shared papers, 2018–2021 · strength 1.27
  4. Wensheng Liu · 13 shared papers, 2018–2021 · strength 1.27
  5. Xianjun Yu · 13 shared papers, 2018–2021 · strength 1.26
  6. Xiaowu Xu · 12 shared papers, 2019–2021 · strength 1.19
  7. Wenyan Xu · 11 shared papers, 2018–2021 · strength 1.06
  8. Mengqi Liu · 8 shared papers, 2019–2021 · strength 0.81
  9. Qiqing Sun · 9 shared papers, 2018–2020 · strength 0.80
  10. Qifeng Zhuo · 6 shared papers, 2020–2021 · strength 0.63
  11. Ye Zeng · 5 shared papers, 2020–2021 · strength 0.53
  12. Wenquan Wang · 2 shared papers, 2023–2024 · strength 0.47
  13. Jin Xu · 4 shared papers, 2018–2019 · strength 0.33
  14. Quanxing Ni · 4 shared papers, 2018–2019 · strength 0.33
  15. Ye Zeng · 3 shared papers, 2019–2021 · strength 0.31
  16. Maozhen Peng · 1 shared paper, 2023 · strength 0.24
  17. Liang Liu · 1 shared paper, 2023 · strength 0.24
  18. Jinbin Jia · 1 shared paper, 2024 · strength 0.23
  19. Liang Liu · 1 shared paper, 2024 · strength 0.23
  20. Zijin Xu · 1 shared paper, 2024 · strength 0.23
  21. Yun Jin · 1 shared paper, 2024 · strength 0.23
  22. Jiahua Zhou · 1 shared paper, 2022 · strength 0.16
  23. Haodong Tang · 1 shared paper, 2022 · strength 0.16
  24. Bo Zhang · 2 shared papers, 2018–2019 · strength 0.16
  25. Mengqi Liu · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.